Irbesartan And Hydrochlorothiazide Crescent Pharma (Hydrochlorothiazide, Irbesartan)

Irbesartan/Hydrochlorothiazide acts on the renin‑angiotensin‑aldosterone system and renal sodium handling to control elevated blood pressure.

• Hypertension: lowers systolic and diastolic pressure in patients with primary hypertension.
• Left ventricular hypertrophy: helps reduce cardiac workload associated with chronic high blood pressure.
• Renal protection in hypertension: slows progression of hypertensive kidney disease by reducing intraglomerular pressure.

• Irbesartan selectively blocks AT1 receptors, preventing angiotensin II‑mediated vasoconstriction and aldosterone release. Hydrochlorothiazide inhibits NaCl reabsorption in the distal convoluted tubule, increasing urinary sodium and water excretion, which together lower peripheral vascular resistance and plasma volume, resulting in reduced blood pressure.

Common Side Effects

• Dizziness or light‑headedness
• Headache
• Fatigue or weakness
• Increased urination
• Electrolyte disturbances (e.g., low potassium)
• Mild gastrointestinal upset

Serious or Rare Side Effects

• Severe dehydration or electrolyte imbalance
• Hyperkalemia or severe hypokalemia
• Acute kidney injury or worsening renal function
• Angioedema or severe facial swelling
• Hypotensive crisis
• Anaphylactic reactions

Before initiating therapy, consider the following precautions:

• Renal function: monitor serum creatinine and eGFR regularly.
• Electrolytes: check potassium and sodium levels, especially when combined with other diuretics.
• Pregnancy: avoid use unless clearly necessary, as safety is not established.
• Elderly patients: start at the lowest effective dose and titrate cautiously.
• Concomitant medications: review for potential interactions that may affect blood pressure or electrolyte balance.
• Store at ambient temperature: keep tablets in the original container, protect from moisture and direct sunlight.

Irbesartan/Hydrochlorothiazide may interact with several medicines.

Major Interactions (Avoid)

• Potassium‑sparing diuretics or supplements: risk of hyperkalemia.
• ACE inhibitors or aliskiren (in diabetes): additive renal effects.
• Lithium: increased lithium levels and toxicity.
• NSAIDs: may blunt antihypertensive effect and impair renal function.
• Strong CYP2C9 inhibitors: may raise irbesartan concentrations.

Moderate Interactions (Monitor Closely)

• Beta‑blockers: additive blood‑pressure lowering effect.
• Calcium channel blockers: may enhance hypotensive response.
• Antidiabetic agents: diuretic‑induced changes in glucose may require dose adjustment.